Companies: 10,795·Total market cap: $144.5T
Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ)

CALTNASDAQHealthcare
$40.00
$-0.04(-0.10%)
Market Cap$2.1B
P/E Ratio—
52W High$43.0
52W Low$15.25
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Calliditas Therapeutics AB (publ) (CALT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001795579 · CALT · NASDAQ · as of Jun 8, 2026

Filing snapshot

176
Total Filings
15F-12B
Latest Form
2024-09-23
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001795579 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2024-04-24
Fiscal Year End
Apr 24, 2024
Accession No.
0001410578-24-000528
Primary Document
calt-20231231x20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001795579 · Accession 0001410578-24-000528

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2024-09-03
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15F-12B15F-12B
15F-12B
2024-09-23
View
SC 13D/ASC 13D/A
AMENDMENT NO. 4 TO SCHEDULE 13D
2024-09-23
View
25-NSE25-NSE
25-NSE
2024-09-20
View
SC TO-T/ASC TO-T/A
FORM SC TO-T/A
2024-09-18
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-09-18
View
SC 13D/ASC 13D/A
AMENDMENT NO. 3 TO SCHEDULE 13D
2024-09-17
View
EFFECTEFFECT
EFFECT
2024-09-16
View
SC TO-T/ASC TO-T/A
FORM SC TO-T/A
2024-09-16
View
2525
FORM 25
2024-09-13
View
S-8 POSS-8 POS
S-8 POS
2024-09-13
View
S-8 POSS-8 POS
S-8 POS
2024-09-13
View
POS AMPOS AM
POS AM
2024-09-13
View
SC 13G/ABeneficial Ownership Report (Amended)
AMENDMENT NO. 3 TO SCHEDULE 13G
2024-09-11
View
SC 13D/ASC 13D/A
AMENDMENT NO. 2 TO SCHEDULE 13D
2024-09-09
View
SC 13D/ASC 13D/A
AMENDMENT NO. 1 TO SCHEDULE 13D
2024-09-03
View
Showing 1–15 of 176 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001795579  |  Exchange: NASDAQ · Healthcare

Calliditas Therapeutics AB (publ) (NASDAQ: CALT) has submitted 176 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001795579, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Calliditas Therapeutics AB (publ)'s most comprehensive regulatory disclosure. The most recent Calliditas Therapeutics AB (publ) 10-K was filed on 2024-04-24 for fiscal year ending 2024. Historical CALT 10-K annual reports are available from 2019 through 2024.

Investors researching Calliditas Therapeutics AB (publ) SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
MORF SEC Filings →KDNY SEC Filings →MYOV SEC Filings →PRVB SEC Filings →LBPH SEC Filings →DICE SEC Filings →DCPH SEC Filings →BLU SEC Filings →
→ CALT Financials→ CALT Earnings→ CALT Insider Trades

Frequently Asked Questions

CALT SEC Filings · 8 questions

Calliditas Therapeutics AB (publ) (CALT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 176 filings and access original documents at no cost. Calliditas Therapeutics AB (publ)'s CIK is 0001795579.

CALT SEC filingsCalliditas Therapeutics AB (publ) SEC documentsfind CALT 10-K